Can Finerenone Alter Glomerular Disease Trajectory? - Takeaways - MDSpire

Can Finerenone Alter Glomerular Disease Trajectory?

Share

1

The FIND-CKD trial included 903 participants with glomerular diseases, assessing the effects of finerenone versus placebo.
2

Finerenone reduced the eGFR decline by 1.22 mL/min/1.73 m² per year after 3 months compared to placebo.
3

In the immunoglobulin A nephropathy subgroup, finerenone decreased urinary albumin-to-creatinine ratio by 47%.
4

Serious adverse events were similar between finerenone (20%) and placebo (21%) groups, with low rates of hyperkalemia.
5

The study faced limitations, including reliance on investigator-reported diagnoses and lack of biopsy confirmation for many participants.